Guardant CRC Blood Test Approved by FDA as a Primary Screening Option

 

• Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage
• Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates
• Guardant Health to host investor conference call and webcast Monday, July 29, at 8:30 a.m. ET / 5:30 a.m. PT

Guardant Health will host an investor conference call and webcast Monday, July 29, at 8:30 a.m. ET / 5:30 a.m. PT to discuss the FDA approval for Shield. A link to live audio of the webcast will be available on the “Investors” section of the company website at investors.guardanthealth.com or directly at this link. The webcast will be archived and available for replay after the event.

https://www.businesswire.com/news/home/20240725240089/en/Shield